Skip to main content
Contact Us
Subscribe
E-Edition
89°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
126.09
-3.40 (-2.63%)
Official Closing Price
Updated: 4:10 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
October 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
6 Global Trends Critical to Patients During the COVID-19 Pandemic
October 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck for Mothers: Helping End Maternal Mortality
September 29, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Death
Exposures
Death
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
October 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Humans, Animals and the Environment - Our Health Is All Connected
October 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Climate Change
Exposures
Climate
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
October 12, 2021
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...
Via
FinancialNewsMedia
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
October 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
October 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
October 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Acceleron Pharma Inc.
September 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
September 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
September 28, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
September 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
September 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Building Sustainable Value for Our Business and Society
September 22, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
September 20, 2021
Via
FinancialNewsMedia
Celebrating the Diversity of Our Workforce
September 20, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
September 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
September 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
September 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
September 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
September 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Improving Medical Care in the Black Community With Family Health Histories
September 08, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.